Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg)-Reference-Cited by-同舟云学术

Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg)

Published:2023-06-12 Issue:2 Volume:6 Page:116-123
ISSN:2582-0370
Container-title:Asploro Journal of Biomedical and Clinical Case Reports
language:en
Short-container-title:Asp Biomed Clin Case Rep

Author:

Okada Masaki¹,Bando Hiroshi²^ORCID,Iwatsuki Noboru¹,Sakamoto Kazuki¹,Ogawa Tomoya¹

Affiliation:

1. Sakamoto Hospital, Higashi Kagawa city, Kagawa, Japan

2. Sakamoto Hospital, Higashi Kagawa city, Kagawa, Japan; Tokushima University/Medical research, Tokushima, Japan

Abstract

The patient is a 66-year-old female being treated for hypertension. She developed a cerebral vascular accident (CVA) in October 2019, and was subsequently diagnosed with type 2 diabetes (T2D) due to an HbA1c level of 9.8%. She began a low carbohydrate diet (LCD) and started taking oral hypoglycemic agents (OHAs) such as metformin and linagliptin. From July 2021, she occasionally experienced anxiety and palpitations, leading to a diagnosis of reactive depression (adjustment disorder). Despite treatment with etizolam as needed, these symptoms persisted. In December 2022, due to an increase in HbA1c levels to 7.7%, metformin was switched to imeglimin (Twymeeg). By April 2023, her HbA1c had decreased to 6.9%, and she reported a sustained sense of well-being without psychosomatic symptoms.

Publisher

Asploro Open Access Publications

Subject

General Medicine

Reference32 articles.

1. Saleem SM, Bhattacharya S, Deshpande N. Non-communicable diseases, type 2 diabetes, and influence of front of package nutrition labels on consumer’s behaviour: Reformulations and future scope. Diabetes Metab Syndr. 2022 Feb;16(2):102422. [PMID: 35150963]

2. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Cusi K, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S49-S67. [PMID: 36507651]

3. EASD. The EASD Annual Meeting will be a hybrid event, providing the option to join us in person in Hamburg, Germany or online via the Virtual Meeting platform. Germany: European Association for the Study of Diabetes; 2023. Available from: https://www.easd.org/annual-meeting/easd-2023.html

4. Bouchi R, Kondo T, Ohta Y, Goto A, Tanaka D, Satoh H, Yabe D, Nishimura R, Harada N, Kamiya H, Suzuki R, Yamauchi T; JDS Committee on Consensus Statement Development. A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes. J Diabetes Investig. 2023 Jan;14(1):151-64. [PMID: 36562245]

5. Horii T, Iwasawa M, Shimizu J, Atsuda K. Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase-4 inhibitors in treatment-naïve patients with type 2 diabetes in Japan. J Diabetes Investig. 2020 Jan;11(1):96-100. [PMID: 31145536]

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improvement of HbA1c, Weight and Fatty Liver by Short Treatment of Imeglimin (Twymeeg);Asploro Journal of Biomedical and Clinical Case Reports;2024-01-20

2. Type 2 Diabetes (T2D) Case with Digestive and Cardiovascular Disorders Treated by EquMet and Twymeeg;Asploro Journal of Biomedical and Clinical Case Reports;2023-09-09

3. Actual Meal of Low Carbohydrate Diet (LCD) for Diabetic Patient Treated by Effective Imeglimin (Twymeeg);Asploro Journal of Biomedical and Clinical Case Reports;2023-07-31